Qrativ (Mayo Clinic - nference Joint Venture)

nference is a joint venture between Mayo Clinic and Qrativ that specializes in activating clinical real-world data through multimodal AI for healthcare research. The company operates a federated AI network connecting data from major healthcare systems, providing access to billions of clinical data points including 10+ billion radiology images, 1.4+ billion clinical notes, 20+ million digitized pathology slides, and over 100 million echocardiogram videos.

The platform centers on transforming unstructured electronic medical record (EMR) data into research-ready datasets through proprietary knowledge graphs, common data models, and advanced AI algorithms. Key capabilities include best-in-class de-identification for structured and unstructured data, anatomical computation platforms for deriving imaging biomarkers, and clinical data quality validation frameworks. The company supports research across seven therapeutic areas including cardiology, oncology, immunology, rare diseases, neurology, infectious diseases, and nephrology.

nference has established partnerships with major pharmaceutical companies, health systems, and research organizations globally. The company has also launched two venture spinoffs: Anumana, focused on ECG-based predictive diagnostics, and Pramana, which enables digital pathology adoption. Their platform supports the design of patient cohorts, exploration of patient journeys, and development of predictive models for clinical researchers and data scientists.

Organizations should consider nference when they need access to large-scale, high-quality real-world clinical data for research purposes, particularly for studies requiring multimodal data integration (imaging, genomics, clinical notes, structured EHR). The platform excels in scenarios requiring federated research across multiple health systems while maintaining data privacy.

Engagements typically involve collaborative research projects, real-world evidence generation for regulatory submissions, or biomarker discovery initiatives. Clients can expect access to pre-curated therapeutic area datasets, AI-powered data extraction from unstructured sources, and support from clinical and data science teams for study design and execution.

nference operates exclusively in healthcare, specifically focusing on clinical research and drug development. The company's federated network includes partnerships with major health systems (Mayo Clinic, Duke Health, Banner Health) and provides therapeutic area expertise across cardiology, oncology, immunology, rare diseases, neurology, infectious diseases, and nephrology. The platform addresses healthcare-specific challenges including HIPAA de-identification, clinical data harmonization using common data models, and extraction of clinical meaning from unstructured medical records, imaging studies, and pathology reports.

Ideal clients are pharmaceutical and biotechnology companies with active drug discovery or clinical development programs, academic medical centers seeking to monetize and leverage their clinical data for research, and life sciences organizations requiring real-world evidence for regulatory submissions or post-market surveillance. Organizations should have dedicated data science or clinical research teams capable of working with large-scale datasets and advanced analytics platforms.